Infliximab for postsurgical endoscopic recurrence of Crohnʼs disease: No trumpets yet

Sorrentino, Dario; Paviotti, Alberto

doi:10.1002/ibd.20965

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By contrast, data related to the effect of infliximab therapy (rather than prophylaxis) for early endoscopic post surgical recurrence of CD are less consistent [5][6][7]. Such strategy would have clear cost and safety advantages over standard prophylaxis with the same drug [8][9][10].…”

Section: Introductionmentioning

confidence: 75%

See 1 more Smart Citation

Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 75%

“…Such strategy would have a number of obvious benefits compared to a standard prophylactic strategy [8][9][10]24]. Published data [5,6] do not clarify whether such strategy is truly effective [7]. Current understanding of biologic agents suggest that they are more effective when used early during the course of the disease [25,26].…”

Section: Discussionmentioning

confidence: 96%

Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Early diagnosis of recurrence will help the clinical management and the patient's quality of life [34]. If patients can be stratified into higher or lower risk groups for recurrence, targeted medical therapy such as anti-TNFa [35][36][37] might prevent or delay the onset of recurrence. Histopathological assessment of the resected specimen for MP may usefully predict surgical recurrence.…”

Section: Discussionmentioning

confidence: 99%

Myenteric plexitis at the proximal resection margin is a predictive marker for surgical recurrence of ileocaecal Crohn's disease

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the design of that study, its extremely short follow-up and the interpretation of its data do not allow any firm conclusion in this regard [59].…”

Section: Can We Treat -Rather Than Prevent -Early Endoscopic Recurrence?mentioning

confidence: 89%

Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows

Sorrentino¹,

Paviotti²,

Fiorino³

2010

CDT

Self Cite

View full text Add to dashboard Cite

Recurrence of Crohn's disease (CD) is extremely frequent after surgery and its prevention remains a fundamental problem in the medical management of these patients. As of today, none of the medications traditionally used to treat the spontaneous disease (i.e. mesalamine, steroids, immunosuppressives and antibiotics) has shown a clear benefit. Recent data, coming from our center and from a small RCT do indicate that infliximab is extremely effective in preventing this complication in the large majority of patients. While additional, larger studies may be desirable, the strength and consistency of the available data suggest that future trials may merely confirm these observations. A number of issues however remain to be solved and include the long term strategy in patients treated for years with infliximab, whether treating early endoscopic lesions may be as effective as preventing them and whether immunosuppressives should be used together with infliximab. A thorough understanding of the mechanisms by which infliximab appears so effective in the postoperative setting may provide us with essential information regarding patients' management and, ultimately, highlight the molecular mechanisms at the very basis of Crohn's disease.

show abstract

Infliximab for postsurgical endoscopic recurrence of Crohnʼs disease: No trumpets yet

Cited by 4 publications

References 8 publications

Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study

Early Diagnosis and Treatment of Postoperative Endoscopic Recurrence of Crohn’s Disease: Partial Benefit by Infliximab—A Pilot Study

Myenteric plexitis at the proximal resection margin is a predictive marker for surgical recurrence of ileocaecal Crohn's disease

Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows

Contact Info

Product

Resources

About